Esperion Therapeutis.Inc. buy Bank of America Co.
Summary
This prediction ended on 16.06.24 with a price of €2.69. The BUY prediction by Bank_of_America_Co_ for Esperion Therapeutis.Inc. saw massive gains of 111.30%. Bank_of_America_Co_ has a follow-up prediction for Esperion Therapeutis.Inc., but this time predicts that Esperion Therapeutis.Inc. is a Sell. Bank_of_America_Co_ has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Esperion Therapeutis.Inc. | 1.408% | 1.408% | 75.000% |
iShares Core DAX® | 1.280% | 1.320% | 13.605% |
iShares Nasdaq 100 | -2.457% | -5.192% | 25.941% |
iShares Nikkei 225® | -2.006% | -1.389% | 8.973% |
iShares S&P 500 | -0.662% | -1.884% | 23.684% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Current prediction by Bank_of_America_Co_ for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
20.06.24
20.06.25
26.07.24